Cellyan Biotechnology Co., Ltd (HKPD)
| Market Cap | 8.16M -52.8% |
| Revenue (ttm) | 13.43M -33.9% |
| Net Income | -1.14M |
| EPS | -0.05 |
| Shares Out | 23.50M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 15,291 |
| Open | 0.3910 |
| Previous Close | 0.4061 |
| Day's Range | 0.3439 - 0.3999 |
| 52-Week Range | 0.3100 - 1.8200 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 7, 2026 |
About HKPD
Cellyan Biotechnology Co., Ltd, an investment holding company, engages in the over-the counter (OTC) pharmaceutical business in Hong Kong and Mainland China. The company provides OTC pharmaceutical cross-border procurement and distribution and e-commerce supply chain services. It also offers customs clearance, drugs enlisting, warehouse, and other logistics services. In addition, it provides value-added services such as labeling, extended storage, product inspection, batch processing, and logistics support, as well as sales of health supplement... [Read more]
Financial Performance
In fiscal year 2026, Cellyan Biotechnology's revenue was $13.43 million, a decrease of -33.87% compared to the previous year's $20.31 million. Losses were -$1.14 million, 4098.6% more than in 2025.
Financial StatementsNews
Cellyan Biotechnology Co., Ltd Receives Nasdaq Notice of Additional Compliance Grace Period
HONG KONG, July 16, 2026 (GLOBE NEWSWIRE) -- Cellyan Biotechnology Co., Ltd (Nasdaq: HKPD) (the "Company"), a leading provider of over the counter (“OTC”) pharmaceutical cross-border e-commerce supply...
Cellyan Biotechnology files $200M mixed securities shelf
16:32 EDT Cellyan Biotechnology (HKPD) files $200M mixed securities shelf
Cellyan Biotechnology Co. files to sell 12.5M Class A ordinary shares for holder
15:22 EDT Cellyan Biotechnology Co. (HKPD) files to sell 12.5M Class A ordinary shares for holder
Cellyan Biotechnology Co., Ltd Receives Nasdaq Notice of Bid Price Deficiency
HONG KONG, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Cellyan Biotechnology Co., Ltd (Nasdaq: HKPD) (the "Company"), a leading provider of over the counter (“OTC”) pharmaceutical cross-border e-commerce supply...
Hong Kong Pharma Digital Announced Results of 2025 Annual Meeting of Stockholders
HONG KONG, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Hong Kong Pharma Digital Technology Holdings Limited (NASDAQ: HKPD) ("HKPD" or the "Company"), a leading provider of over the counter (“OTC”) pharmaceutica...
DCS Announces Q3 2025 Quarterly Financial Statements
San Diego, California--(Newsfile Corp. - December 1, 2025) - Direct Communication Solutions, Inc. (CSE: DCSI) (FSE: 7QU0), a leading provider of information technology solutions for the Internet of Th...
Hong Kong Pharma Digital Technology Holdings Limited Reports Financial Results for the Six Months Ended September 30, 2024
HONG KONG , March 28, 2025 /PRNewswire/ -- Hong Kong Pharma Digital Technology Holdings Limited (NASDAQ: HKPD) ("HKPD" or the "Company"), a leading provider of over the counter ("OTC") pharmaceutical ...
Hong Kong Pharma Digital Technology Holdings Limited Announces Closing of Initial Public Offering
NEW YORK , Jan. 16, 2025 /PRNewswire/ -- Hong Kong Pharma Digital Technology Holdings Limited ("Hong Kong Pharma" or the "Company") (NASDAQ: HKPD), a leading provider of over the counter ("OTC") pharm...
Hong Kong Pharma announces pricing of 1.4M ordinary share IPO
Hong Kong Pharma (HKPD) Digital Technology Holdings Limited announced the pricing of its initial public offering of an aggregate of 1.4M ordinary shares at a public offering price of $4.00…
Hong Kong Pharma opens at $3.50, IPO priced at $4 per share
Hong Kong Pharma (HKPD) Digital Technology Holdings, a provider of OTC pharmaceutical cross-border e-commerce supply chain services in Hong Kong, priced its initial public offering of an aggregate of ...